To test the effectiveness of GM.CD40L vaccine in combination with an adjuvant CCL21 in patients with advanced lung adenocarcinoma, a phase I/II randomized trial was carried out; however, improved overall survival and progression-free survival were not observed [33]. This evidence concerns the gene CD40LG and lung adenocarcinoma.